Consensus of Expert Recommendations for the Safe Administration of Brolucizumab in Neovascular Age-related Macular Degeneration

• 발행기관: 대한안과학회
• 저자명: Jae Ryong Song Kyu Hyung Park Se Woong Kang Hee Seung Chin Seung Young Yu Young-Hoon Park Yu Cheol Kim Ji Eun Lee Sun Taek Lim June-Gone Kim Chang Ryong Kim Min Sagong Hyun Sub Oh Christopher Seungkyu Lee Se Joon Woo
• 간행물 정보: 『The Korean Journal of Ophthalmology』Vol.39 No.4, 362~368쪽, 전체 7쪽
• 주제분류: 인문학 > 역사학
• 파일형태: PDF
• 발행일자: 2025.08.31

국문 초록

Brolucizumab offers improved anatomical outcomes and extended dosing intervals compared to aflibercept, reducing treatment burden. However, postmarketing surveillance and real-world studies have highlighted safety concerns, including intraocular inflammation (IOI), retinal vasculitis, and retinal vascular occlusion, necessitating risk management strategies. To address these concerns, a comprehensive review of clinical trials, real-world data, and safety reports were conducted by an expert panel. This consensus report offers practical, evidence-based recommendations to ensure the safe administration of brolucizumab in patients with neovascular age-related macular degeneration (nAMD). The safety management of brolucizumab in patients with nAMD starts with selecting suitable patient profiles through thorough risk assessments. Educating patients about the risk of inflammation and its symptoms is important, as prompt recognition and early medical attention may help improve outcomes. Close monitoring with frequent follow-ups and the use of widefield fundus imaging or peripheral fundus examination are also necessary for early detection and management of complications. Effective management of IOI includes considering discontinuation of brolucizumab, alternative anti–vascular endothelial growth factor therapies, and corticosteroid treatments based on anatomical location and severity of IOI. Differentiating noninfectious IOI from infectious endophthalmitis is essential to ensure appropriate intervention and safeguard vision. In conclusion, this consensus recommendations emphasized the importance of the evidence-based and patient-centered stepwise approaches that should be considered when prescribing brolucizumab to patients with nAMD. This is not an absolute guideline, and the management should be adapted according to the ophthalmic conditions and the patients’ opinions after thorough discussions.

목차

Introduction

Materials and Methods

Consensus Recommendations for Safety Management of Brolucizumab

Discussion

Conclusion

Supplementary Materials

References

키워드

Age-related macular degeneration Brolucizumab Intraocular inflammation Retinal vasculitis Uveitis